Navigation Links
MedinCell to Explore Controlled-Release Drug Delivery Partnerships at the World Animal Health Congress
Date:12/2/2011

SAN DIEGO and MONTPELLIER, France, Dec. 2, 2011 /PRNewswire/ -- MedinCell, a leading developer of low-cost, controlled-release drug delivery technology, will be exploring partnerships for key companion and food animal markets with industry leaders at the Terrapinn World Animal Health Congress in Kansas City (December 6-8, 2011).

"MedinCell's biodegradable polymer technology offers exceptional control over the duration of drug release, thereby making small molecules—and even peptides—cost effective for the companion and food animal markets," said Dr. Alexandre Melin, Director of Animal Health for MedinCell. "Our platform's inherent flexibility enables us to design single-injection products that release drug molecules systemically over just a few days, or across multiple-months. With some APIs, we can achieve therapeutic plasma levels throughout an entire year," Dr. Melin (alexandre.melin@medincell.eu) continued.

Dr. Anh Nguyen, MedinCell Founder and CEO, explained, "MedinCell has experience formulating molecules for chemocastration, diabetes, pain control and parasitology. Our MedinGel™ technology brings a strong environmental benefit to animal health brands by reducing the required drug cargo, and therefore the amount of API cleared by the animals. This can also lead to a substantial reduction in product cost for animal health companies."

"MedinCell recognizes that the demand for protein production is increasing, and requires novel approaches to support the growing global population," commented Dr. Melin, who welcomes meeting requests at the World Animal Health Congress to discuss controlled-release strategies. "We look forward to designing novel products that improve product efficiency and animal treatment for the food animal industry," concluded Dr. Melin.

About MedinCell

MedinCell's patent-pending drug delivery technology, MedinGel, entraps drug molecules in a polymer matrix after injected. By limiting the initial drug burst, MedinCell can design formulations that extend release duration. With MedinGel, substantially less API cargo is required than for products designed for oral administration, which is a pivotal consideration for cost-sensitive markets such as animal health. MedinCell SA is headquartered in Montpellier, France, and recently launched formulation and R&D activities at its US subsidiary, MedinCell Corporation, in San Diego, California. Contact information for both facilities is available at www.medincell.com.

Information on the Terrapinn World Animal Health Congress is available online: http://www.terrapinn.com/2011/world-animal-health-congress/index.stm

 

 

CONTACT:  Chris Hoover, MedinCell Corporation, +1-858-216-4573, chris.hoover@medincell.com


'/>"/>
SOURCE MedinCell
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. A Worldwide Phase III Clinical Trial Seeks U.S. Patients to Explore Investigational Drug Phenoxodiol
2. SPIRIT II Explores Long-Term Performance of XIENCE V Stent
3. New Survey Explores the Impact of Insulin Injections and Communications Between Patients and Healthcare Providers
4. 42 Top U.S. Scientists and Specialists Explore Cutting-Edge Innovations to Defend America From Dangerous Zoonotic Diseases
5. Research Explores the Effects of Stem Cell Source and Patient Age on Stem Cell Transplantation Outcomes
6. Urologist and Allergist Explore Link Between Allergies and Interstitial Cystitis
7. Webinar to Explore FDA Draft REMS Guidance and Its Implications for Lifecycle Management
8. New Manhattan Research Report Explores the Growing Consumer Demand for Online Health Video and How Pharma Marketers Can Leverage this Format
9. Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis
10. Advanced Life Sciences to Explore Strategic Alternatives to Maximize Shareholder Value
11. Retrospective Analysis Explores LYSTEDA®s Ability to Reduce Sleep Interruptions in Women With Cyclic Heavy Menstrual Bleeding
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ORLANDO, Fla. , Feb. 10, 2016 /PRNewswire/ ... of technologies and products that help uncover the ... and Swift Biosciences Inc., a developer of innovative ... collaboration and co-marketing partnership aimed at enabling translational ... few as a couple hundred tumor and normal ...
(Date:2/10/2016)... Fla. , Feb. 9, 2016  Until recently, ... were surgery or liposuction. Thankfully, the FDA approved the ... them to death. Coolsculpting was originally approved in 2010 ... the thighs and now the chin. With this add-on ... Center can use a smaller applicator, the CoolMini, to ...
(Date:2/10/2016)... India , February 10, 2016 ... The "Personalized Medicine, Targeted Therapeutics and Companion Diagnostic ... Trends, Technologies, Participants, and Environment" research report indicates ... worth over $149 billion by 2020 growing at ... up of companion diagnostics and targeted therapeutics and ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... Dr. ... office is now offering a variety of comprehensive procedures for facial enhancement. The ... facial volume restoration, lip enhancement and nasal reshaping. , As a result, ...
(Date:2/10/2016)... , ... February 10, 2016 , ... Ongoing news of ... Life Care Association™ (ALCA) to conduct a survey that takes a closer look at ... today illustrates the prevalence and causes of TBI among the aging population, and identifies ...
(Date:2/10/2016)... ... February 10, 2016 , ... United Benefit Advisors (UBA), ... latest addition to its growing list of Partner Firms. S.S. Nesbitt is ... Orlando to Huntsville and in between. , Harnessing the experience and insights of ...
(Date:2/10/2016)... ... 10, 2016 , ... AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company ... and full year ended December 31, 2015 on Monday, February 29, 2016 after the ... investment community following the release at 4:30 PM ET. Investors interested in participating by ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... time Emmy award winner and inspirational speaker Jan Fox will serve as keynote ... Speaking Boldly will provide participants with tools to more effectively communicate with their ...
Breaking Medicine News(10 mins):